
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Post?9/11: Shock lingers in tangible ways. What every Girl Scout should know. We, the children. Pediatricians: First line of defense. Eye on Washington






